Wang M Y, Day J, Chao L, Chao J
Department of Pharmacology, Medical University of South Carolina, Charleston 29425.
Adv Exp Med Biol. 1989;247B:1-8. doi: 10.1007/978-1-4615-9546-5_1.
A new and specific tissue kallikrein-binding protein was identified in mammalian serum and in secreted transformed-cell culture media (Chao et al., Biochem. J. 239: 325-331, 1986). We have designated this kallikrein-binding protein as "kallistatin". Human kallistatin has been purified from serum, using chromatographic steps including DEAE-Sephadex, hydroxylapatite, Cibacron blue-Sepharose, Sephacryl S200, and preparative polyacrylamide gel electrophoresis. The purified kallistatin consists of a single polypeptide chain with an apparent molecular weight of approximately 54 kDa and isoelectric point of approximately 5.0. Kallistatin was eluted as a single peak on reverse-phase HPLC. The purified kallistatin and 125I-labelled human tissue kallikrein form a approximately a 92 kDa SDS- and heat-stable complex. The complex formation is pH dependent and is inhibited by 0.1% (W/V) of deoxycholate or SDS but not by 0.5% (W/V) of Triton X-100, digitonin, Lubrol or CHAPS. A approximately 54 kDa protein was identified in partially purified kallistatin by polyclonal anti-kallistatin antibodies in Western blot analysis and by its binding to 125I-labelled-human tissue kallikrein in ligand blotting. The role of kallistatin in regulating tissue kallikrein activity and metabolism may now be evaluated.
在哺乳动物血清和分泌的转化细胞培养基中发现了一种新的特异性组织激肽释放酶结合蛋白(Chao等人,《生物化学杂志》239: 325 - 331, 1986)。我们将这种激肽释放酶结合蛋白命名为“激肽抑制蛋白”。人激肽抑制蛋白已从血清中纯化出来,采用了包括DEAE - 葡聚糖凝胶、羟基磷灰石、Cibacron蓝 - 琼脂糖凝胶、Sephacryl S200和制备型聚丙烯酰胺凝胶电泳在内的色谱步骤。纯化后的激肽抑制蛋白由一条单多肽链组成,表观分子量约为54 kDa,等电点约为5.0。激肽抑制蛋白在反相高效液相色谱上以单峰形式洗脱。纯化后的激肽抑制蛋白与125I标记的人组织激肽释放酶形成一种约92 kDa的SDS和热稳定复合物。复合物的形成依赖于pH值,并且受到0.1%(W/V)的脱氧胆酸盐或SDS的抑制,但不受0.5%(W/V)的 Triton X -
100、洋地黄皂苷、Lubrol或CHAPS的抑制。在蛋白质印迹分析中,通过多克隆抗激肽抑制蛋白抗体在部分纯化的激肽抑制蛋白中鉴定出一种约54 kDa的蛋白质,并且在配体印迹中通过其与125I标记的人组织激肽释放酶的结合鉴定出该蛋白。现在可以评估激肽抑制蛋白在调节组织激肽释放酶活性和代谢中的作用。